Vitruvias Therapeutics and Sunny Pharmtech link up to co-develop generics

Published: 15-Apr-2015
Research & Development Pharmaceutical

Each company will have a 50% stake in the product portfolio


Vitruvias Therapeutics, a privately held US-based generic drug development company, has formed a partnership with Taiwanese API and finished dose drug development company Sunny Pharmtech to co-develop a varied portfolio of generic drugs.

The agreement will leverage the research, development, and distribution capabilities of each company to develop and commercialise generic products in markets that currently exceed US$400m.

Each company will have a 50% stake in the product portfolio, and the first ANDA could be filed in the fourth quarter of 2015.

  • Companies:
  • Vitruvias Therapeutics
See more

You may also like

Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

Read more
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  5. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Subscribe now